• Survival significantly improved for patients receiving BRAF inhibitor plus SRS vs SRS alone as assessed from the time of SRS induction (p < 0.00001), from the time of brain metastasis diagnosis (p < 0.00001), or from the time of primary diagnosis (p = 0.02)• Dual therapy was also associated with improved local control (p = 0.03)• Intracranial hemorrhage was higher in patients receiving BRAF inhibitors plus SRS than in those receiving SRS alone (p = 0.004). This evidence concerns the gene BRAF and intracranial hemorrhage.